Brind.

Vinay Prasad returned to lead CBER at the FDA on August 12, 2025.

3 reports, 2 independent Updated Aug 12

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 3
Developments: 2
Repetition: 33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Vinay Prasad returned to lead CBER at the FDA on August 12, 2025.

Who's involved

What this event is mainly about

FDA Vinay Prasad

How it developed

Newest first. Tap a step to see who reported it.

Aug 12Prasad resumed leadership of CBER at the FDA.1 source
- Pharmaceutical Technology
Aug 11Prasad resumed his FDA role; he called for drug removal over safety concerns, amid political pressure.1 source
- Quartz

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Vinay Prasad
US hematologist–oncologist

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 12Pharmaceutical TechnologyPrasad’s shock FDA return reignites regulatory uncertainty In a U-turn that caught many in the industry off guard, Vinay Prasad is back at the US Food and Drug Administration (FDA). On 29 July, Prasa
Aug 11QuartzControversial FDA regulator back 12 days after resigning Dr. Vinay Prasad returned to the Food & Drug Administration less than two weeks after resigning , following intense scrutiny from right wing c
Aug 1Pharmaceutical TechnologyGeorge Tidmarsh to sub in as FDA CBER head following Prasad’s shock exit Fresh off his appointment as the head of the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (